Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, ottobre 21
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
BridgeBio Oncology Therapeutics Inc
BBOT
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$2.74
0.02
0.74%
Ult. Agg.: Oct 21, 2:24 PM
$2.80
0.08
2.94%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Confronta
Rapporto azionario
Privacy Manager
BridgeBio Oncology Financials
BridgeBio Oncology (BBOT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate
BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(705.20) per share which missed the analyst consensus estimate of $(0.57) by 123619.3 percent. This is a 24.49 percent decrease over losses of $(566.46) per
Benzinga Newsdesk
PRO
BridgeBio Oncology Q1 EPS $(526.11) Down From (54.230) YoY,
BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(526.11).This is a 870.15 percent decrease over losses of $(54.23) per share from the same period last year.
Benzinga Newsdesk
PRO
BridgeBio Oncology Q4 EPS $(0.49) Beats $(0.56) Estimate
BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.56) by 13.12 percent.
Benzinga Newsdesk
PRO
BridgeBio Oncology Q3 EPS $(1.03) Misses $(0.40) Estimate
Benzinga Newsdesk
